KR840006677A - Method for preparing treponema palidium antigen - Google Patents

Method for preparing treponema palidium antigen Download PDF

Info

Publication number
KR840006677A
KR840006677A KR1019830005374A KR830005374A KR840006677A KR 840006677 A KR840006677 A KR 840006677A KR 1019830005374 A KR1019830005374 A KR 1019830005374A KR 830005374 A KR830005374 A KR 830005374A KR 840006677 A KR840006677 A KR 840006677A
Authority
KR
South Korea
Prior art keywords
antigen
dna
treponema
antibody
bacteriophage
Prior art date
Application number
KR1019830005374A
Other languages
Korean (ko)
Inventor
에이. 로베트 마이클
Original Assignee
로저 지이. 디트젤
더 레젠트스 오브 더 유니버시티 오브 캘리포니아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 로저 지이. 디트젤, 더 레젠트스 오브 더 유니버시티 오브 캘리포니아 filed Critical 로저 지이. 디트젤
Publication of KR840006677A publication Critical patent/KR840006677A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/571Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses for venereal disease, e.g. syphilis, gonorrhoea
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

내용 없음No content

Description

트레포네마 팔리듐 항원의 제조방법Method for preparing treponema palidium antigen

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음As this is a public information case, the full text was not included.

제1도는 탄수화물에 기인되는 설질을 갖는 특별한 단백질 항원의 유전정보를 갖는 샤론 30클로운(Tp4D) 및 이것의 서브클로운 PAW 329의 DNA지도이고,FIG. 1 is a DNA map of Sharon 30-Crown (Tp4D) and its sub-Crown PAW 329 with the genetic information of a particular protein antigen with a sulphate derived from carbohydrate,

제2도는 단백질 항원의 유정정보를 갖는 세가지 샤론 30 클로운(Tp3A, Tp1C 및 Tp2D)의 DNA 지도임.2 is a DNA map of three Sharon 30 clones (Tp3A, Tp1C and Tp2D) with protein antigen well information.

Claims (39)

박티리오파지 백터(bacteriophrge vector)의 DNA를 절단하여 첫 번째 DNA단편(fragmeut)을 산출하고, 상기 DNA 단편을 트레포네마 팔리듐(Tre ponema pallidam)으로 부터의 두 번째 DNA단편과 결합시키는데 상기 첫 번째 및 두 번째 DNA단편은 재조합될 수 있어서 재조합된 DNA를 형성하고, 상기 재조합된 DNA를 생명력이 있는 박테리오파지에 봉입(packaging)하여 박테리오파지 클로운(clone)을 형성하고, 적합한 숙주(host)를 상기 박테리오 파지 클로운으로 감염시켜 플라크(plague)를 형성하고, 트레포네마 팔리듐의 항체와 반응하는 항원을 갖는 클라크를 선별하는 것을 포함하는 트레포네마 팔리듐 항체와 반응하는 항원의 제조방법.The DNA of the bacteriophrge vector is cleaved to yield the first DNA fragment, which is then combined with a second DNA fragment from Tre ponema pallidam. The second and second DNA fragments can be recombined to form a recombinant DNA, the recombinant DNA is packaged in a viable bacteriophage to form a bacteriophage clone, and a suitable host is described above. A method for producing an antigen that reacts with a treponema palladium antibody, which comprises infecting with a bacteriophage clone to form plaques and selecting a Clarke having an antigen that reacts with an antibody of treponema palidium. 제1항에 있어서, 상기 첫 번째 DNA단편이 상기 박테리오파지를 좌측 아암(arm)단편, 중앙부 충진(stuffer)단편 및 우측 아암 단편으로 절단하고 상기 중앙부 충진 단편을 상기 좌측 및 우측 단편으로부터 제거하여 제공되는 제조방법.The method of claim 1, wherein the first DNA fragment is provided by cleaving the bacteriophage into a left arm fragment, a center stuffer fragment, and a right arm fragment and removing the center fill fragment from the left and right fragments. Manufacturing method. 제2항에 있어서, 상기 박테리오파지 벡터가 샤론 30(charon 30)인 제조방법.The method of claim 2, wherein the bacteriophage vector is Sharon 30. 제3항에 있어서, 상기 숙주가 에세리키아 콜리(Escherichia Coli)인 제조방법.4. The method of claim 3, wherein said host is Escherichia coli. 제1항에 있어서, 상기 선별된 플라크에 있는 트레포네마 팔리듐 항체와 반응하는 항원이 단백질 항원 및 프로테아제(protease)에 저항성이고 열에 불안정한 단백질 항원으로 분리되는 제조방법.The method of claim 1, wherein the antigen that reacts with treponema palladium antibodies in the selected plaques is separated into protein antigens and protease resistant and heat labile protein antigens. 제4항에 있어서 상기 박테리오파지의 DNA가 제한효소(restriction.enzyne) Bam HI에 의해 절단되는 제조방법.The method of claim 4, wherein the DNA of the bacteriophage is cleaved by restriction enzyme (restriction.enzyne) Bam HI. 제4항에 있어서, 상기 두 번째 DNA단편이 트레포네마 팔리듐의 DNA를 제한 효소 Sau 3AI로 절단되는 제조방법.The method of claim 4, wherein the second DNA fragment is cleaved from the DNA of treponema palladium with the restriction enzyme Sau 3AI. DNA재조합 기술에 의해 생성된 트레포네마 팔리듐 항체와 반응하는 항원은 생물학적 액체 참플에 첨가하고, 상기 항원이 상기 참플에 존재하는 트레포네마 팔리듐의 항체와 반응하는지 여부를 결정하여 생물학적 액체에 트레포네마 팔리듐 항체의 존재를 탐지하는 방법.Antigens that react with treponema palladium antibodies produced by DNA recombination techniques are added to a biological liquid chapel and determine whether the antigen reacts with antibodies of treponema palladium present in the chapel. Method for detecting the presence of treponema palidium antibodies. DNA재조합 기술에 의해 산출되고 트레포네마 팔리듐 항체와 반응하는 항원이 포함된 조성물.A composition comprising an antigen produced by a DNA recombination technique and reacting with a treponema palidium antibody. 상기 박테리오파지의 DNA에 결합된 트레포네마 팔리듐 유전자가 포함되고, 상기 박테리오 파지는 트레포네마 팔리듐의 항체와 반응하는 항원을 산출할 수 있는 박테리오파지.A bacteriophage comprising a treponema palidium gene bound to the DNA of the bacteriophage, wherein the bacteriophage may yield an antigen that reacts with an antibody of treponema palidium. 제10항에 있어서, 상기 박테리오파지가 샤록 30인 박테리오 파지.The bacteriophage of claim 10, wherein the bacteriophage is Charok 30. 12. 제11항에 있어서, 상기 박테리오파지가 트레포네마 팔리듐의 항체에 특이적으로 반응하는 분자량 46,000달톤(dalton), 37,000달톤, 23,000달톤 및 18,000달톤인 단백질 항원을 산출할 수 있는 박테리오파지.The bacteriophage of claim 11, wherein the bacteriophage is capable of yielding protein antigens having a molecular weight of 46,000 daltons, 37,000 daltons, 23,000 daltons, and 18,000 daltons that specifically react with an antibody of treponema palidium. 샤론 30의 DNA를 절단하여 첫 번째 DNA단편을 산출하고, 상기 첫 번째 DNA단편을 트레포네마 팔리듐으로 부터의 두 번째, DNA단편에 결합시키는데 상기 첫 번째 및 두 번째 단편은 재조합 가능하여 재조합 DNA를 산출하고, 상기 재조합 DNA를 생명력이 있는 샤론 30에 봉입하여 트레포네마 팔리듐의 항체와 반응하는 항원을 생산할 수 있는 박테리오파지 클로운을 형성하는 샤론 30의 변형방법.The DNA of Sharon 30 was cut to yield the first DNA fragment, and the first DNA fragment was bound to a second, DNA fragment from treponema palidium, the first and second fragments being recombinable and thus recombinant DNA. The method of modifying Sharon 30 to form a bacteriophage clone capable of calculating and encapsulating the recombinant DNA in vital 30 Sharon 30 to produce an antigen that reacts with an antibody of Treponema palidium. 제13항에 있어서, 샤론 30 DNA가 제한 효소 Bam HI으로 절단되는 방법.The method of claim 13, wherein the Sharon 30 DNA is cleaved with the restriction enzyme Bam HI. 제14항에 있어서, 트레포네마 팔리듐으로 부터의 DNA단편이 트레포네마 팔리듐 DNA를 제한효소 Sau AI로 절단하여 제조되는 방법.The method of claim 14, wherein the DNA fragments from treponema palladium are prepared by cleaving treponema palladium DNA with restriction enzyme Sau AI. 샤론 30의 DNA를 절단하여 첫 번째 DNA단편을 산출하고, 상기 첫 번째 DNA단편을 트레포네마 팔리듐으로 부터의 두 번째 단편과 결합시키는데 상기 첫 번째 및 두 번째 단편은 재조합되어 재조합 DNA를 산출할 수 있고, 상기 재조합 DNA를 생명력이 있는 샤론 30에 봉입시켜 샤론 30클로운을 산출하고, 적합한 숙주를 상기 샤론 30클로운으로 감염시켜 플로크를 형성하고, 트레포네마 팔리듐의 항체와 반응하는 항원을 갖는 상기 플라크로부터 변형된(modified)샤론 30박테리오 파지를 선별하여 제조된 트레포네마팔리듐의 항체와 반응하는 항원을 생산할 수 있는 변형된 샤론 30박테리오 파지.The DNA of Sharon 30 is cut to yield the first DNA fragment, which is then combined with a second fragment from treponema palidium, where the first and second fragments are recombined to yield recombinant DNA. Encapsulating the recombinant DNA in vital 30 Sharon 30 to yield Sharon 30-klow, infecting a suitable host with the Sharon 30-klow to form a floc, and reacting with an antibody of treponema palladium. A modified Sharon 30 bacteriophage capable of producing an antigen that reacts with an antibody of treponemapallidium prepared by selecting a modified Sharon 30 bacteriophage from the plaque having an antigen. 제16항에 있어서, 상기 샤론 30 DNA가 제한 효소 Bam HI으로 절단되는 변형된 샤론 30박테리오 파지.17. The modified Sharon 30 bacteriophage of claim 16, wherein the Sharon 30 DNA is cleaved with the restriction enzyme Bam HI. 제16항에 있어서, 트레포네마 팔리듐으로 부터의 DNA단편이 트레포네마 팔리듐 DNA를 제한효소 Sau AI로 절단하여 제조되는 변형된 샤론 30박테리오 파지.The modified Sharon 30 bacteriophage of claim 16, wherein the DNA fragment from treponema palladium is prepared by cleaving treponema palladium DNA with a restriction enzyme Sau AI. 제5항에 따라 제조되고 트레포네마 팔리듐의 항체와 반응하는 항원이 함유된 조성물.A composition prepared according to claim 5 and containing an antigen which reacts with an antibody of treponema palladium. 제5항에 따라 제조되고 트레포네마 팔리듐의 항체와 반응하는 프로테아제(protease)저항성이고 열에 불안정한 단백질 항원이 함유된 조성물.A composition comprising a protease resistant and heat labile protein antigen prepared according to claim 5 and reacting with an antibody of treponema palladium. 제1항에 따라 산출된 항원을 생물학적 액체의 샘플에 첨가하고, 상기 항원이 샘플에 존재하는 트레포네마 팔리듐의 항체와 반응하는 지의 여부를 결정하여 트레포네마 팔리듐 감염을 결정하는 방법.A method for determining treponema palladium infection by adding an antigen produced according to claim 1 to a sample of a biological liquid and determining whether the antigen reacts with an antibody of treponema palidium present in the sample. 트레포네마 팔리듐의 항체에 반응성인 단백질 항원을 산출할 수 있고, ATCC번호 39237가 동일한 특성을 갖는 에세리키아 콜리균주인 미생물.A microorganism capable of producing a protein antigen reactive to an antibody of treponema palladium, wherein ATCC No. 39237 is an Escherichia coli strain having the same characteristics. 트레포네마 팔리듐의 항체에 반응성이고 프로테아제에 저항성이며 열에 불안정한 단백질 항원을 산출할 수 있으며, ATCC번호 39238과 동일한 특성을 갖는 에세리키아 균주인 미생물.A microorganism which is an Escherichia strain capable of producing protein antigens that are responsive to the antibodies of treponema palladium, are resistant to proteases, and are heat-stable. 제22 또는 23항에 있어서, 동결건조 형태로 되어 있는 미생물.The microorganism according to claim 22 or 23, which is in lyophilized form. 제22 또는 23항의 미생물에 의해 생산되고 트레포네마 팔리듐의 항체와 반응하는 항원.An antigen produced by the microorganism of claim 22 or 23 and reacting with an antibody of treponema palidium. 제8항에 있어서, 항원이 제1항에 따라 산출된 항원.The antigen of claim 8, wherein the antigen is calculated according to claim 1. 제9항에 있어서, 제1항의 방법으로 산출된 항원.The antigen of claim 9, which is produced by the method of claim 1. 제9항의 항원의 면역학적으로 효과적인 용향을 동물에 투여하여 트레포네마 팔리듐과 면역 반응성인 항체를 상승시키는 방법.A method of elevating an antibody that is immunoreactive with treponema palladium by administering an immunologically effective flavor of the antigen of claim 9 to the animal. 제28항에 있어서, 상기 항원이 제25항의 항원인 방법.The method of claim 28, wherein said antigen is the antigen of claim 25. 트레포네마 팔리듐의 항체와 반응하는 항원의 유전 정보를 갖는 트레포네마 팔리듐 유전자가 미생물의 DNA(plnsmid DNA)에 결합되어 에세리키아 콜리 균주인 미생물.A microorganism, which is an Escherichia coli strain in which a treponema palidium gene having genetic information of an antigen reacting with an antibody of treponema palidium is bound to a microorganism DNA (plnsmid DNA). 프로테아제에 저항성이고 열에 불안정한 트레포네마 팔리듐의 항원이 포함된 백신제제(Vaccination agent).Vaccination agent containing an antigen of treponema palidium that is resistant to protease and heat labile. 제31항에 있어서, 프리인더(Freundi)보조제가 포함된 백신제제.32. The vaccine formulation of claim 31 comprising a preundi adjuvant. 트레포네마 팔리듐의 항체와 반응하며 프로테아제 저항성이고, 열에 불안정한 단백질 항원이 포함된 조성물.A composition comprising a protease resistant, heat labile protein antigen that reacts with an antibody of treponema palladium. 제33항에 있어서, 상기 프로테아제에 저항성이고 열얼 불안정한 항원이 90,000달톤 정도의 분있량을 갖는 조성물.34. The composition of claim 33, wherein said protease resistant and thermally labile antigen has a fraction of about 90,000 Daltons. 제23항에서 정의된 미생물에 의해 생산된 프로테아제 저항성이고 열에 불안정한 항원이 포함된 조성물.A composition comprising a protease resistant and heat labile antigen produced by a microorganism as defined in claim 23. 트레포네마 팔리듐의 항원을 니트로셀룰로스 종이에 옮기고, 상기 니트로셀룰로스 종이를 생물학적 액체의 샘플에 담가서, 상기 항원이 상기 샘플에 존재하는 트레포네마 팔리듐의 항체와 반응하는지의 여부를 결정하는 것을 포함하는 트레포네마 팔리듐 감염의 결정방법.Transfer the antigen of treponema palladium to nitrocellulose paper and immerse the nitrocellulose paper in a sample of biological liquid to determine whether the antigen reacts with the antibodies of treponema palladium present in the sample. A method for determining treponemal palidium infection, which comprises. 제36항에 있어서, 상기항원이 제33항의 항원인 방법.The method of claim 36, wherein said antigen is the antigen of claim 33. 플라스미드 백터의 DNA를 절단하여 첫 번째 DNA단편을 산출하고, 상기 첫 번째 DNA단편을 트레포네마 팔리듐으로 부터의 두 번째 DNA단편과 결합하는데 상기 첫 번째 외 두 번째 DNA단편은 재조합이 가능하여 재조합 DNA를 형성하고, 상기 재조합 DNA를 형성하고, 상기 재조합 DNA를 적당한 숙주에 형질도입하고, 상기 현질도입된 숙주의 콜로니(colony)를 번식시키고, 트레포네마 팔리듐의 항체와 반응하는 항원을 생산하는 콜로니를 선별하는 것을 포함하여 트레포네마 팔리듐 항체와 반응하는 항원을 제조하는 방법.The DNA of the plasmid vector is cut to yield a first DNA fragment, and the first DNA fragment is combined with a second DNA fragment from treponema palidium. Form DNA, form the recombinant DNA, transfect the recombinant DNA into a suitable host, propagate colonies of the transduced host, and produce antigens that react with antibodies of treponema palladium A method for producing an antigen that reacts with treponema palladium antibody, including selecting colonies. 적당한 백터의 DNA를 절단하여 첫 번째 DNA단편을 산출하고, DNA단편을 트레포네마팔리듐으로 부터의 두 번째 DNA단편과 결합시키는데 상기 첫 번째 및 두 번째 DNA단편은 재조합이 가능하여 재조합 DNA를 형성하고, 상기 재조합 DNA를 적당한 숙주에 형질도입하고, 상기 형질도입된 숙주를 번식시켜 트레포네마 팔리듐의 항체와 반응하는 항원을 제조하는 방법.DNA from the appropriate vector is cut to yield the first DNA fragment, which is then combined with a second DNA fragment from treponemapallium, which is recombinable to form recombinant DNA. And transducing the recombinant DNA to a suitable host, and propagating the transduced host to produce an antigen that reacts with an antibody of treponema palladium. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019830005374A 1982-11-12 1983-11-12 Method for preparing treponema palidium antigen KR840006677A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44139182A 1982-11-12 1982-11-12
US66/441.391 1982-11-12

Publications (1)

Publication Number Publication Date
KR840006677A true KR840006677A (en) 1984-12-01

Family

ID=23752699

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019830005374A KR840006677A (en) 1982-11-12 1983-11-12 Method for preparing treponema palidium antigen

Country Status (5)

Country Link
EP (1) EP0126765A1 (en)
JP (1) JPS59502131A (en)
KR (1) KR840006677A (en)
GB (1) GB2157696A (en)
WO (1) WO1984001961A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4868118A (en) * 1986-09-30 1989-09-19 Board Of Regents, The University Of Texas System Cloning and expression of the 47-kilodalton antigen of treponema pallidum
CA2193870C (en) 1995-12-25 2000-07-18 Nobuyuki Ise Treponema pallidum fused antigen and assay for anti-treponema pallidum antibodies using the same fused antigen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4294817A (en) * 1977-11-25 1981-10-13 International Diagnostic Technology, Inc. Method of fluoro immunoassay
US4288426A (en) * 1980-03-20 1981-09-08 Research Corporation Serological test for syphilis

Also Published As

Publication number Publication date
WO1984001961A1 (en) 1984-05-24
GB2157696A (en) 1985-10-30
EP0126765A1 (en) 1984-12-05
JPS59502131A (en) 1984-12-27
GB8412158D0 (en) 1984-06-20

Similar Documents

Publication Publication Date Title
Stålhammar-Carlemalm et al. Protein rib: a novel group B streptococcal cell surface protein that confers protective immunity and is expressed by most strains causing invasive infections.
Bastardo et al. Preparation and characterization of antisera to electrophoretically purified SA11 virus polypeptides
Fischetti et al. Size variation of the M protein in group A streptococci.
Gravekamp et al. Alpha C protein as a carrier for type III capsular polysaccharide and as a protective protein in group B streptococcal vaccines
CA1204384A (en) Protection against dental caries
Pettersson Structural proteins of adenoviruses: VI. On the antigenic determinants of the hexon
NO152774B (en) PROCEDURE FOR PREPARING AN ANTIGEN PREPARATION EFFECTING DENTAL-KARIES
EP0656014B1 (en) Protein rib, a cell surface protein that confers immunity to many strains of the group b streptococcus; process for purification of the protein, reagent kit and pharmaceutical composition
SK56394A3 (en) Anti-vaccine of streptococcus suis infection and method of its production
US5766594A (en) Poultry mycoplasma antigens and recombinant vectors containing the gene as well as diagnostics and vaccines utilizing the same
Tortorello et al. Identification of multiple cell surface antigens associated with the sex pheromone response of Streptococcus faecalis
Lévesque et al. Streptococcus salivarius fimbriae are composed of a glycoprotein containing a repeated motif assembled into a filamentous nondissociable structure
Harano et al. An antiserum to a synthetic fimbrial peptide of Actinobacillus actinomycetemcomitans blocked adhesion of the microorganism
Erdogan et al. Molecular analysis of group B protective surface protein, a new cell surface protective antigen of group B streptococci
Dubreuil et al. Production and purification of heat-stable enterotoxin b from a porcine Escherichia coli strain
Movitz et al. Physico-and immunochemical properties of staphylococcal protein A extracellularly produced by a set of mutants from Staphylococcus aureus Cowan I
Ellis et al. Identification of Aeromonas salmonicida extracellular protease as a protective antigen against furunculosis by passive immunization
KR840006677A (en) Method for preparing treponema palidium antigen
Brady et al. Monoclonal antibody-mediated modulation of the humoral immune response against mucosally applied Streptococcus mutans
Gigliotti et al. Pneumocystis carinii host origin defines the antibody specificity and protective response induced by immunization
Stewart et al. Cross‐protection from Bacteroides nodosus vaccines and the interaction of pili and adjuvants
US4737363A (en) Bacteroides nodosus vaccine
EP0362274B1 (en) Treatment and diagnosis of footrot using the basic protease of bacteroides nodosus
Lugowski et al. Enterobacterial common antigen-tetanus toxoid conjugate as immunogen
Corbeil et al. Cloning and expression of genes encoding Haemophilus somnus antigens

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application